Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Wendys Co — how do they compare? Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B), while Wendys Co trades at $7.53 (market cap $1.45B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 92.5× Wendys Co's market cap, and Wendys Co pays a 3.68% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| VRTX | WEN | |
|---|---|---|
Market Cap | $134.06B | $1.45B |
Sector | Health | Consumer Cyclical |
52-Week High | $557.96 | $9.89 |
52-Week Low | $376.62 | $6.17 |
Enterprise Value | $128.18B | $5.18B |
Dividend Yield | — | 3.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Wendy's stock (WEN) trades at $7.61, down 5.23% over 24 hours, reflecting recent volatility after takeover speculation faded. The stock shows a bearish technical trend with key support at $7 and resistance at $8. Fundamentally, the company has beaten EPS estimates for three consecutive quarters but faces declining net income margins, from 7.58% in 2025 to 5.72% projected for 2026. Recent news highlights CEO Bob Wright's turnaround efforts, including a new marketing chief appointment to address quality and traffic declines.
The outlook is mixed: valuation ratios like P/E of 11.54 and P/S of 0.66 appear attractive relative to peers, but execution risks persist amid competitive pressures. Analyst consensus is cautious with 64.71% hold ratings, though the $8.13 price target implies modest upside. Key risks include sustained traffic declines and high debt levels, with debt-to-asset ratio rising to 55.68% in 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
